The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor DNA (ctDNA) dynamics as early biomarkers of response to enfortumab vedotin plus pembrolizumab (EVP) in advanced urothelial carcinoma (aUC).
 
Mohammad Jad Moussa
No Relationships to Disclose
 
Emanuele Crupi
No Relationships to Disclose
 
Zachariah Thomas
No Relationships to Disclose
 
Amishi Shah
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Exelixis; Pfizer/EMD Serono
Research Funding - 4D Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst); Incyte
 
Jianjun Gao
Research Funding - Summit Therapeutics
 
Sangeeta Goswami
No Relationships to Disclose
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Summit Therapeutics; Takeda (Inst)
 
Cindy Jiang
No Relationships to Disclose
 
Andrew Johns
Stock and Other Ownership Interests - Lilly; Merck; Stryker
 
Michael Glover
No Relationships to Disclose
 
Nizar Tannir
Stock and Other Ownership Interests - Amgen; BioCryst; Johnson & Johnson/Janssen; Spdr S&P Pharmaceuticals ETF; Surface Oncology; Vanguard Health Care
Honoraria - Bristol-Myers Squibb; Eisai; Intellisphere; Ipsen; Merck Sharp & Dohme; Oncorena
Research Funding - Arrowhead Pharmaceuticals Inc. (Inst); Bristol Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)
 
Arlene Siefker-Radtke
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bicycle Therapeutics; Biohaven Pharmaceuticals; EMD Serono; G1 Therapeutics; Gilead Sciences; Immunomedics; Janssen; Loxo; Merck; NCCN; Pfizer; Seagen; Taiho Pharmaceutical
Research Funding - Bicycle Therapeutics (Inst); Janssen (Inst); Loxo (Inst); Merck (Inst); NIH (Inst)
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Matthew Campbell
Honoraria - Curio Science; Eisai; Eisai; Exelixis; Merck; MJH Life Sciences; OnViv; Pfizer; Targeted Oncology
Research Funding - Exelixis (Inst); Genentech (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - DAVA Oncology; Exelixis
 
Omar Alhalabi
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Bicycle Therapeutics; Cardinal Health; Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst)